Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Puma Biotechnology, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Women and men who are ≥18 years old at signing of informed consent
Eastern Cooperative Oncology Group (ECOG) status of 0 to 2
Provide written informed consent to participate in the study and for circulating tumor DNA screening
Must be able to provide blood sample(s) for HER2 mutation testing
Participants with imaging or histologically confirmed, HR-positive, HER2-negative MBC who are presently receiving or have received CDK4/6 inhibitor as a prior therapy in any setting, or participants with imaging or histologically confirmed metastatic cervical cancer
At least one measurable lesion, as defined by RECIST v1.1
You may not be if
Participants with breast cancer with known HER2-positive or HER2-amplified tumors
Participants with breast cancer with HR-negative tumors
Participants who have received HER2-directed TKI
Participants with previously documented somatic KRAS activating mutation
Clareo Health | HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib
